RxSight (RXST) Competitors $14.43 -0.09 (-0.62%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$14.46 +0.04 (+0.24%) As of 04/17/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. LIVN, LMAT, ENOV, NVCR, CNMD, WRBY, CDRE, KMTS, LQDA, and TNDMShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include LivaNova (LIVN), LeMaitre Vascular (LMAT), Enovis (ENOV), NovoCure (NVCR), CONMED (CNMD), Warby Parker (WRBY), Cadre (CDRE), Kestra Medical Technologies (KMTS), Liquidia (LQDA), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry. RxSight vs. LivaNova LeMaitre Vascular Enovis NovoCure CONMED Warby Parker Cadre Kestra Medical Technologies Liquidia Tandem Diabetes Care LivaNova (NASDAQ:LIVN) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Which has stronger valuation & earnings, LIVN or RXST? LivaNova has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.25B1.54$17.55M$1.1431.21RxSight$139.93M4.18-$48.61M-$0.72-20.04 Is LIVN or RXST more profitable? LivaNova has a net margin of 1.91% compared to RxSight's net margin of -23.92%. LivaNova's return on equity of 13.81% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets LivaNova1.91% 13.81% 7.07% RxSight -23.92%-14.00%-12.51% Does the media favor LIVN or RXST? In the previous week, RxSight had 1 more articles in the media than LivaNova. MarketBeat recorded 13 mentions for RxSight and 12 mentions for LivaNova. LivaNova's average media sentiment score of 1.24 beat RxSight's score of 0.67 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive RxSight 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk & volatility, LIVN or RXST? LivaNova has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Does the MarketBeat Community believe in LIVN or RXST? LivaNova received 354 more outperform votes than RxSight when rated by MarketBeat users. Likewise, 69.71% of users gave LivaNova an outperform vote while only 62.96% of users gave RxSight an outperform vote. CompanyUnderperformOutperformLivaNovaOutperform Votes40569.71% Underperform Votes17630.29% RxSightOutperform Votes5162.96% Underperform Votes3037.04% Do analysts rate LIVN or RXST? LivaNova presently has a consensus price target of $61.17, indicating a potential upside of 71.91%. RxSight has a consensus price target of $37.60, indicating a potential upside of 160.57%. Given RxSight's higher probable upside, analysts plainly believe RxSight is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88RxSight 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do institutionals & insiders believe in LIVN or RXST? 97.6% of LivaNova shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Comparatively, 9.4% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryLivaNova beats RxSight on 14 of the 19 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightOphthalmic goods IndustryMedical SectorNASDAQ ExchangeMarket Cap$584.29M$10.74B$5.29B$7.35BDividend YieldN/A0.96%5.12%4.31%P/E Ratio-17.3934.8921.7117.77Price / Sales4.182.67379.3997.68Price / CashN/A14.5338.2234.64Price / Book3.232.246.443.98Net Income-$48.61M$224.27M$3.21B$247.44M7 Day Performance2.49%-1.54%2.82%1.82%1 Month Performance-43.92%-16.31%-8.66%-6.98%1 Year Performance-72.12%-25.57%11.33%1.49% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight3.0101 of 5 stars$14.43-0.6%$37.60+160.6%-72.7%$584.29M$139.93M-17.39220Analyst ForecastGap DownLIVNLivaNova3.5695 of 5 stars$35.46+4.4%$61.17+72.5%-31.4%$1.93B$1.25B84.432,900Positive NewsGap DownLMATLeMaitre Vascular3.1243 of 5 stars$83.78+1.2%$95.25+13.7%+36.9%$1.89B$219.86M45.78490Positive NewsENOVEnovis2.3824 of 5 stars$32.28+0.8%$58.50+81.2%-43.3%$1.84B$2.11B-14.746,800NVCRNovoCure3.3343 of 5 stars$16.55+0.3%$34.50+108.5%+29.3%$1.82B$605.22M-11.821,320Upcoming EarningsAnalyst ForecastNews CoverageGap UpCNMDCONMED4.6482 of 5 stars$50.91-1.6%$77.20+51.6%-33.3%$1.57B$1.31B12.014,100News CoveragePositive NewsWRBYWarby Parker3.3471 of 5 stars$14.92+0.8%$22.71+52.2%+17.8%$1.55B$771.32M-55.263,030Analyst UpgradeNews CoverageGap UpCDRECadre3.4772 of 5 stars$31.24+1.5%$37.00+18.4%-7.3%$1.27B$567.56M37.642,240KMTSKestra Medical TechnologiesN/A$23.83-1.9%$27.67+16.1%N/A$1.18B$45.82M0.00300Earnings ReportAnalyst ForecastQuiet Period ExpirationNews CoverageLQDALiquidia2.2647 of 5 stars$13.83+2.7%$26.63+92.5%-1.0%$1.18B$14.00M-8.4850Insider TradeGap UpTNDMTandem Diabetes Care4.2164 of 5 stars$17.03-0.2%$43.88+157.7%-46.9%$1.13B$940.20M-8.822,600Positive News Related Companies and Tools Related Companies LivaNova Alternatives LeMaitre Vascular Alternatives Enovis Alternatives NovoCure Alternatives CONMED Alternatives Warby Parker Alternatives Cadre Alternatives Kestra Medical Technologies Alternatives Liquidia Alternatives Tandem Diabetes Care Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXST Stock Free RXST Stock Alerts